Zoetis' Rough Patch Deepens as Institutional Investor Trims Stake and CFO Transition Looms
Published on 08/09/2026 at 17:52 | Redaktion boerse-global.de
The selloff in Zoetis shares shows no signs of letting up. The animal-health giant's stock closed Friday at €62.84, hovering just 0.87% above its 52-week low, after a 6.29% single-day drop that followed another round of bearish analyst commentary. The latest blow came from an unexpected corner: Community Trust & Investment Co. disclosed it had trimmed its position in the company, adding to a growing pile of negative signals that have weighed on the stock since the company's disappointing second-quarter results landed more than a month ago.
Since the start of the year, the shares have shed 41.47% of their value, and they now sit more than half below the record high of €137.00 reached last August. The stock is trading nearly 6% beneath its 50-day moving average, a technical indicator that chart-watchers read as a sign of persistent downward momentum.
Guidance Cut and a Stalled US Pet Market
The root of the trouble traces back to Zoetis' quarterly report, which revealed a business caught between weakening demand and intensifying competition. Second-quarter revenue came in flat year over year at $2.5 billion, with the US companion-animal segment stumbling badly — sales there tumbled 11%. Generic competition eroded sales of key products including Cerenia and Convenia, while Librela underperformed and the dermatology franchise, including Simparica Trio, faced pricing pressure from softer end-market demand.
Management responded by slashing its full-year outlook. Adjusted earnings per share are now expected to land between $6.15 and $6.25, while revenue guidance was trimmed to a range of $9.12 billion to $9.32 billion. Adjusted net income is projected at $2.57 billion to $2.62 billion. The company attributed the revision to sluggish demand in the US pet market and a more competitive landscape.
The damage has been compounded by a series of additional setbacks. A lead-plaintiff deadline in a securities class action passed roughly two weeks ago, knocking another 7.1% off the share price. The recently announced acquisition of teleradiology provider VitalRADS has been met with a 3.1% decline since it was made public. All told, the stock has fallen 15.6% since the earnings report.
When a business faces turbulence, the last thing you need is a compliance gap adding to your liabilities. A free toolkit with 41 ready-to-use templates and checklists helps you document workplace risks properly and keep your operation on solid ground. Download the free Risk Assessment Toolkit
A Split on Wall Street
The analyst community finds itself unusually divided on Zoetis' prospects. JPMorgan trimmed its price target from $130 to $115 but held firm on its Overweight rating — a signal that the bank sees the current weakness as a near-term earnings problem rather than a structural one. Morgan Stanley took a far more cautious stance, establishing a new target of $85. UBS had already cut its target to $85 and downgraded the stock to Neutral on July 27, while another house reduced its target to $99 in late July. William Blair, for its part, reaffirmed a neutral stance following both the quarterly results and the CFO transition.
That wide spread in targets — from $85 to $115 — reflects genuine uncertainty about how deep and how long the US pet-care slump will run.
New Leadership at the Finance Helm
Adding to the sense of flux, Zoetis is shaking up its executive ranks. Jay Saccaro, recruited from GE HealthCare, steps in on August 17 as Executive Vice President, Chief Financial Officer and Chief Operating Officer — a newly created dual role. Current CFO Wetteny Joseph will transition to an advisory position the same day, supporting the CEO on financial matters into early 2027.
The company is also taking operational steps to address the US weakness. A new US sales leadership team has been appointed, and the company plans to redirect advertising and rebate budgets toward its most profitable programs rather than pursuing across-the-board price cuts.
Not Everything Is Sour
Despite the gloom, there are pockets of strength worth noting. International revenue grew 6% to $1.2 billion, with gains across both companion-animal and livestock segments. In the US, the livestock business posted a 23% increase — a reminder that the company's problems are concentrated in specific regions and product lines rather than reflecting a company-wide malaise.
Management continues to return capital to shareholders, confirming a quarterly dividend of $0.432 per share payable September 1. Through year-end, the company has funneled $1.6 billion back to shareholders via dividends and buybacks, while directing roughly $350 million into research and development and about $225 million into capital investments.
On the M&A front, Zoetis is pressing ahead with its diagnostics strategy. Beyond the VitalRADS deal, the company is working to close the $160 million acquisition of Neogen's animal genomics business, agreed back in March.
Whether these measures — the guidance reset, the leadership changes, the strategic redirection — will be enough to restore investor confidence remains an open question. For now, the stock sits near its lows, the institutional selling continues, and the market is waiting for evidence that the US pet owner is ready to open their wallet again.
